$AXON

SMITH PATRICK W sold $5.1M of AXON

SMITH PATRICK W (CHIEF EXECUTIVE OFFICER) sold 10,000 shares of AXON ENTERPRISE, INC. (AXON) at an average of $508.99 ($501.99–$513.38, $5.09M total) across 11 trades on 2026-09-08 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · SMITH PATRICK W
Published Sep 10, 2026, 8:45 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 10, 2026, 9:09 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$AXON
Bearish
medium confidence
Mentioned
$AXON
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$AXONBearishLow
01

Why it matters

The insider sale may influence short-term price action, but longer-term fundamentals remain unchanged.

02

Market read

AXON shares may experience short-term volatility due to the insider sale.

03

What to watch

Potential upcoming product launches or earnings could offset the negative signal.

Relevance 5/10Novelty 7/10Timing: filed 2026-09-10

Background

Form 4 filings disclose insider transactions; a CEO sale of this magnitude is noteworthy.

Company-level read

Ticker impact

$AXONBearishMedium confidence
Context

CEO Patrick Smith sold $5.1M of AXON shares via a 10b5-1 plan, reducing his stake to 3.12M shares.

Expected impact

Possible modest downside pressure over the next few days.

Evidence & confidence

A $5M sale by the CEO is material and disclosed for the first time; markets often react negatively to insider sell-offs of this size.

Market effects

Minimal impact on the broader medical device sector.

Limited to U.S. markets where AXON trades.

Low global relevance.

Counterpoint

The sale could be a routine 10b5-1 execution unrelated to company fundamentals.

Key entities

  • Patrick Smith

    Chief Executive Officer of Axon Enterprise, Inc.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$AXONHighAI 9/10

Axon’s (AXON) Dilution Fears Look Overstated

Axon Enterprise (AXON) stock fell after announcing a $1B convertible-note offering, but analysts argue dilution fears are overstated. The notes carry 0% interest, convert at $652.06, and are hedged to $1,049.94. Q2 revenue rose 35% to $904M, marking 10 straight quarters of over 30% growth. Management raised full-year revenue growth outlook to 32-34%. AXON has a Strong Buy consensus rating, with an average price target of $719.55.

$AXONHighAI 8/10

Why Did Axon Stock Fall Ten Percent On A Convertible That Pays No Interest?

Axon Enterprise (AXON) shares dropped 9.8% after announcing a $1.0 billion convertible note offering with a 0% coupon. The market interpreted this as a sign of cash flow challenges despite strong revenue growth (34.6% YoY). The company cited inventory investments and rising component costs. AXON's stock is now 43% below its 52-week high, trading at 11x trailing revenue with shrinking margins.

$AXONHighAI 9/10

Axon Q2FY26 Results: Revenue rises 35% to $904 million, guidance raised

Axon Enterprise reported Q2FY26 revenue of $904M, up 35% YoY, and raised full-year guidance to 32-34% growth. Software & services revenue rose 36% to $398M, while connected devices revenue grew 35% to $507M. Platform solutions revenue surged 123% to $150M. The company plans a $1B convertible note offering due 2031, with net proceeds for general corporate purposes and capped call transactions. Shares were up 0.50% in premarket trading.

$AXONHighAI 8/10

Full Transcript: Axon Enterprise Q2 2026 Earnings Call - (AXON)

Axon Enterprise (AXON) reported a record Q2 2026 with 39% growth, driven by demand for Dedrone, Taser 10, and Axon Body 4. The company raised its full-year revenue guidance to 32-34% growth, citing strong bookings and market expansion. Management highlighted investments in AI and public safety technologies, emphasizing trust and data privacy.

$AXONMedAI 8/10

Axon Rebounded 6% Wednesday. Here’s What Could Drive the Stock Through 2026

Axon Enterprise's stock rebounded 6% to $468 on Wednesday after a 10% drop following a $1 billion convertible notes offering. The company expects 32-34% revenue growth in 2026, with strong Q4 growth anticipated. Analysts maintain bullish targets, citing Axon's faster expansion compared to competitors like Motorola Solutions. The stock has an implied upside of 56% based on a valuation model target of $706.